NCT00368277 is a Phase 3 clinical trial of Aliskiren in Hypertension, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT00368277?

NCT00368277 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT00368277?

Interventions in NCT00368277: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine.

What condition does NCT00368277 study?

NCT00368277 studies Hypertension.

Is NCT00368277 still recruiting?

NCT00368277 is currently completed. Last updated 28 February 2011.

Are results published for NCT00368277?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2011-02-28 · How we verify

NCT00368277

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients ≥ 65 Years Old With Systolic Essential Hypertension

Completed Phase 3 Results posted Last updated 28 February 2011

What this trial tests

Phase 3 trial testing Aliskiren in Hypertension in 901 participants. Completed in 1 February 2008.

Timeline

1 September 2006

Primary endpoint
1 February 2008

1 February 2008

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	901
Start date	1 September 2006
Primary completion	1 February 2008
Estimated completion	1 February 2008
Sites	1 location across United States

Drugs / interventions tested

Aliskiren (ALISKIREN) — full drug profile →
Ramipril (RAMIPRIL) — full drug profile →
Hydrochlorothiazide (hydrochlorothiazide) — full drug profile →
Amlodipine (amlodipine) — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

65 and older, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12
Time frame: Baseline and Week 12

Sponsor's own description

Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.
Baschiera F, Chang W, Brunel P, AGELESS Study Group. · · 2014 · cited 4× · PMID 25061313 · DOI 10.2147/vhrm.s63725

Verify or expand the search:

Other trials of Aliskiren

Trials testing the same drug.

NCT06718062 — Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia · Phase 4 · completed
NCT00667719 — A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Ess · Phase 3 · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00368277 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 28 February 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00368277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing